ADPT
Price:
$4.69
Market Cap:
$692.15M
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory develo...[Read more]
Industry
Biotechnology
IPO Date
2019-06-27
Stock Exchange
NASDAQ
Ticker
ADPT
According to Adaptive Biotechnologies Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 745.89M. This represents a change of 4.35% compared to the average of 714.80M of the last 4 quarters.
The mean historical Enterprise Value of Adaptive Biotechnologies Corporation over the last ten years is 3.59B. The current 745.89M Enterprise Value has changed 1.98% with respect to the historical average. Over the past ten years (40 quarters), ADPT's Enterprise Value was at its highest in in the December 2020 quarter at 8.08B. The Enterprise Value was at its lowest in in the June 2018 quarter at 0.
Average
3.59B
Median
3.91B
Minimum
871.85M
Maximum
7.74B
Discovering the peaks and valleys of Adaptive Biotechnologies Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 285.34%
Maximum Annual Enterprise Value = 7.74B
Minimum Annual Increase = -71.70%
Minimum Annual Enterprise Value = 871.85M
Year | Enterprise Value | Change |
---|---|---|
2023 | 871.85M | -21.23% |
2022 | 1.11B | -71.70% |
2021 | 3.91B | -49.49% |
2020 | 7.74B | 285.34% |
2019 | 2.01B | -57.74% |
2018 | 4.76B | 0.63% |
The current Enterprise Value of Adaptive Biotechnologies Corporation (ADPT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.96B
5-year avg
3.13B
10-year avg
3.59B
Adaptive Biotechnologies Corporation’s Enterprise Value is greater than Verve Therapeutics, Inc. (323.17M), less than Beam Therapeutics Inc. (2.01B), greater than Caribou Biosciences, Inc. (177.59M), greater than Sana Biotechnology, Inc. (551.82M), less than VectivBio Holding AG (848.58M), greater than Kinnate Biopharma Inc. (71.17M), less than Royalty Pharma plc (18.40B), greater than Ikena Oncology, Inc. (45.73M), greater than CohBar, Inc. (-4477266.00), greater than Hepion Pharmaceuticals, Inc. (5.35M), greater than Rain Therapeutics Inc. (7.16M), less than Krystal Biotech, Inc. (5.10B), greater than AVROBIO, Inc. (-85302404.00), greater than Enveric Biosciences, Inc. (202.96K), greater than Elevation Oncology, Inc. (18.49M), greater than Zura Bio Limited (-9969663.00), greater than Reneo Pharmaceuticals, Inc. (25.69M), less than Legend Biotech Corporation (7.40B), less than Vir Biotechnology, Inc. (835.43M), less than Apellis Pharmaceuticals, Inc. (3.90B),
Company | Enterprise Value | Market cap |
---|---|---|
323.17M | $410.62M | |
2.01B | $2.07B | |
177.59M | $182.92M | |
551.82M | $582.73M | |
848.58M | $1.06B | |
71.17M | $124.99M | |
18.40B | $11.74B | |
45.73M | $82.52M | |
-4477266.00 | $1.45M | |
5.35M | $4.62M | |
7.16M | $44.01M | |
5.10B | $5.48B | |
-85302404.00 | $5.24M | |
202.96K | $3.31M | |
18.49M | $35.67M | |
-9969663.00 | $178.25M | |
25.69M | $60.84M | |
7.40B | $7.51B | |
835.43M | $980.57M | |
3.90B | $3.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adaptive Biotechnologies Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Adaptive Biotechnologies Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Adaptive Biotechnologies Corporation's Enterprise Value?
What is the highest Enterprise Value for Adaptive Biotechnologies Corporation (ADPT)?
What is the 3-year average Enterprise Value for Adaptive Biotechnologies Corporation (ADPT)?
What is the 5-year average Enterprise Value for Adaptive Biotechnologies Corporation (ADPT)?
How does the current Enterprise Value for Adaptive Biotechnologies Corporation (ADPT) compare to its historical average?